Avenue Therapeutics Inc. (NASDAQ: ATXI)
$1.9200
+0.0400 ( +1.59% ) 5.1K
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
Market Data
Open
$1.9200
Previous close
$1.8800
Volume
5.1K
Market cap
$3.96M
Day range
$1.8500 - $1.9600
52 week range
$1.6000 - $15.0000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| s-8 | Registration statements | 4 | Jul 12, 2024 |
| 8-k | 8K-related | 15 | Jun 26, 2024 |
| 8-k | 8K-related | 14 | May 23, 2024 |
| 8-k | 8K-related | 16 | May 15, 2024 |
| 10-q | Quarterly Reports | 56 | May 15, 2024 |
| 8-k | 8K-related | 16 | May 13, 2024 |
| 424b3 | Other | 3 | May 10, 2024 |
| effect | Other | 1 | May 10, 2024 |
| 424b5 | Other | 3 | May 10, 2024 |
| corresp | Comment letters | 1 | May 08, 2024 |